
In mice, the particles heated neighboring tumor cells, appeared on MRI, and killed more cancer cells than the original therapy.
Some cancer cells slip past even the most precise treatments and then grow back. Researchers at Nagoya University in Japan may have found a way to reach them. The team improved a light-based cancer treatment by adding tiny iron particles. In mice, their therapy shrank tumors more effectively and killed nearby cancer cells that the original treatment cannot target. Called a “photothermal bystander effect,” this offers a new way of reaching cancer cells that would otherwise survive. The treatment also grew stronger with each round of light. The findings were published in the Journal of Nanobiotechnology.
Light-based cancer treatment and its limits
The original treatment, called near-infrared photoimmunotherapy (NIR-PIT), uses an antibody that finds a protein called EGFR on cancer cells. The antibody carries a dye that reacts to near-infrared light. When doctors shine the light on a tumor, the targeted cancer cells burst within minutes, while healthy tissue is not affected. This is important for patients with head and neck cancer.
Surgery for these cancers can leave patients unable to chew, swallow or speak, but light therapy can destroy the tumor while preserving these functions. Japan was the first country to approve the treatment for recurrent head and neck cancer, under a conditional approval in 2020. It is now in late-stage clinical trials in the United States.
However, the treatment has two weak points. Tumors are not uniform, so some cancer cells carry the target protein and others do not. Cells without the protein escape treatment and can cause the cancer to return. Doctors also have no easy way to see whether the antibody has reached the tumor because the dye’s glow can only be seen near the surface and fades under light.
Cancer-seeking antibody + light-activated dye + iron oxide
To solve both problems, a team led by Dr. Kazuhide Sato, senior author and lecturer at Nagoya University’s Graduate School of Medicine, attached iron oxide particles, each only about 20 nanometers across, to the antibody. The researchers call this treatment NIR-PICT³.
“Before this study, nanoparticles and antibodies could not reach the tumor because they were captured in the liver or spleen,” Sato said. “The size is very critical.”
Injected into the bloodstream of mice, the tiny particles collected in tumors, which turned dark on MRI scans within hours. This let the researchers see where the drug had gone. Sato said this strong build-up of the drug in tumors after a simple injection was the biggest surprise of the study.
The iron particles also heat up when the near-infrared light shines on them. This heat spreads to neighboring cancer cells, with and without the target protein. To test this, the team used mice with mixed tumors containing both types of cancer cells. The new treatment shrank the entire tumor, including cells the original therapy misses. “We named this the photothermal bystander effect,” Sato said. “This is a new concept.” In lab tests on human cancer cells, the particles also triggered chemical reactions that further damaged them.

Interestingly, the treatment also became stronger with each round of light. The first round opened the tumor’s blood vessels, so more particles could enter and collect inside it. Each later round produced more heat. In mice whose tumors all carried the target protein, tumors shrank and the animals lived longer. Four of 10 treated mice showed complete remission, as did three of six mice whose tumors contained both types of cancer cells (with and without the target protein). In safety tests, treated mice showed no significant weight loss, and blood tests showed no signs of liver damage.

Adapting for other cancers and next steps
Sato, an oncologist by training, hopes to eventually test the treatment in patients. Similar iron oxide particles, though larger, are already approved for use in MRI scans, which may make this step easier. In lab tests on human cancer cells, the researchers also showed that the antibody can be swapped to target other cancer proteins, so the approach could be adapted to different cancers.
So far, the results come from cell and mouse studies, and more work is needed before testing in people. Near-infrared light reaches only a few centimeters into the body, so deep tumors may need special light-delivery devices. The long-term effects of iron in the body also need further study. Next, the team plans to develop even smaller particles for clearer imaging.
Paper information:
Kohei Matsuoka, Mizuki Yamada, Ryu Okada, Mibuko Shimada, Mikina Yoshida, Rika Fukushima, Kanna Umeda, Ayano Ohashi, Chiemi Oka, Ayako Kato, Misae Shimizu, Chiaki Koike, Akira Ito, Mitsuo Sato and Kazuhide Sato, 2026. Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy, Journal of Nanobiotechnology, 24:975. DOI: https://doi.org/10.1186/s12951-026-05148-w
Funding information:
This work was supported by JSPS KAKENHI (21K07217, 25K03451, 25K22916), the JST FOREST Program (JPMJFR2017), AMED Seeds A (26ym0126807j0005, A-226), MEXT’s Advanced Research Infrastructure for Materials and Nanotechnology in Japan (ARIM Japan), JST Tongali, and research scholarships or grants from the Toyota Physical and Chemical Research Institute, the Sumitomo Electric Group CSR Foundation, the Takeda Science Foundation, the SGH Foundation, the Japanese Society for Thermal Medicine, The Chemo-Sero-Therapeutic Research Institute, the Suzuki-Kenzo Scholarship, the Terumo Science Foundation, the Tatematsu Foundation, and the Iketani Science Foundation.
Expert contact:
Kazuhide Sato Graduate School of Medicine Nagoya University Email: sato.kazuhide.k5@f.mail.nagoya-u.ac.jp
Media contact:
Merle Naidoo International Communications Office Nagoya University Email: icomm_research@t.mail.nagoya-u.ac.jp
Top image:
Illustration of the NIR-PICT³ treatment in action: (1) Antibodies (mAb) carrying a light-activated dye (IR700) and tiny iron particles (green) attach to cancer cells in a tumor. The dye’s glow and the iron particles let researchers track the drug using fluorescence imaging and MRI. When near-infrared (NIR) light shines on the tumor, (2) the targeted cells burst, (3) the particles heat up, and (4) they trigger damaging chemical reactions. (5) The light also opens up the tumor’s blood vessels, letting more particles in. (6) The heat then destroys nearby cancer cells that the drug could not target. Credit: Adapted from Matsuoka et al., Journal of Nanobiotechnology (2026), CC BY-NC-ND 4.0





